Evidence map›Paper›PMID 37667227›Full record

ArticleBMC medicine2023

Fluorescence-tagged salivary small extracellular vesicles as a nanotool in early diagnosis of Parkinson's disease.

Simran Rastogi, Komal Rani, Sanskriti Rai, Rishabh Singh, Prahalad Singh Bharti, Vaibhav Sharma, Jyoti Sahu, Vrinda Kapoor, Poorvi Vishwakarma, Sumit Garg and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Simran Rastogi *Department of Biophysics, All India Institute of Medical Sciences, New Delhi, 110029, India.
Komal Rani *Department of Biophysics, All India Institute of Medical Sciences, New Delhi, 110029, India.
Sanskriti RaiDepartment of Biophysics, All India Institute of Medical Sciences, New Delhi, 110029, India.
Rishabh SinghDepartment of Biophysics, All India Institute of Medical Sciences, New Delhi, 110029, India.
Prahalad Singh BhartiDepartment of Biophysics, All India Institute of Medical Sciences, New Delhi, 110029, India.
Vaibhav SharmaDepartment of Health, Education, and Technology, Luleå University of Technology, 97187, Luleå, Sweden.
Jyoti SahuDepartment of Biophysics, All India Institute of Medical Sciences, New Delhi, 110029, India.
Vrinda KapoorSchool of Interdisciplinary Research, Indian Institute of Technology Delhi, New Delhi, 110016, India.
Poorvi VishwakarmaDepartment of Biophysics, All India Institute of Medical Sciences, New Delhi, 110029, India.
Sumit GargDepartment of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, 110029, India.
Shivajirao Lahu GholapDepartment of Chemistry, Indian Institute of Technology Delhi, New Delhi, 110016, India.
Krishna Kishore InampudiDepartment of Biophysics, All India Institute of Medical Sciences, New Delhi, 110029, India.
Gyan Prakash ModiDepartment of Pharmaceutical Engineering & Technology, Indian Institute of Technology BHU, Varanasi, 221005, India.
Neerja RaniDepartment of Anatomy, All India Institute of Medical Sciences, New Delhi, 110029, India.
Madhavi TripathiDepartment of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, 110029, India.
Achal SrivastavaDepartment of Neurology, All India Institute of Medical Sciences, New Delhi, 110029, India.
Roopa RajanDepartment of Neurology, All India Institute of Medical Sciences, New Delhi, 110029, India.
Fredrik NikolajeffDepartment of Health, Education, and Technology, Luleå University of Technology, 97187, Luleå, Sweden.
Saroj KumarDepartment of Biophysics, All India Institute of Medical Sciences, New Delhi, 110029, India. saroj.kumar@ltu.se.ORCID http://orcid.org/0000-0001-7029-1163

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundParkinson's disease is generally asymptomatic at earlier stages. At an early stage, there is an extensive progression in the neuropathological hallmarks, although, at this stage, diagnosis is not possible with currently available diagnostic methods. Therefore, the pressing need is for susceptibility risk biomarkers that can aid in better diagnosis and therapeutics as well can objectively serve to measure the endpoint of disease progression. The role of small extracellular vesicles (sEV) in the progression of neurodegenerative diseases could be potent in playing a revolutionary role in biomarker discovery.

methodsIn our study, the salivary sEV were efficiently isolated by chemical precipitation combined with ultrafiltration from subjects (PD = 70, healthy controls = 26, and prodromal PD = 08), followed by antibody-based validation with CD63, CD9, GAPDH, Flotillin-1, and L1CAM. Morphological characterization of the isolated sEV through transmission electron microscopy. The quantification of sEV was achieved by fluorescence (lipid-binding dye-labeled) nanoparticle tracking analysis and antibody-based (CD63 Alexa fluor 488 tagged sEV) nanoparticle tracking analysis. The total alpha-synuclein (α-syn

resultsWe observed a significant increase in total sEVs concentration in PD patients than in the healthy control (HC), where fluorescence lipid-binding dye-tagged sEV were observed to be higher in PD (p = 0.0001) than in the HC using NTA with a sensitivity of 94.34%. In the prodromal PD cases, the fluorescence lipid-binding dye-tagged sEV concentration was found to be higher (p = 0.008) than in HC. This result was validated through anti-CD63 tagged sEV (p = 0.0006) with similar sensitivity of 94.12%. We further validated our findings with the ELISA based on α-syn

conclusionsIn this study, for the first time, we have found that the fluorescence-tagged sEV has the potential to screen the progression of disease with clinically acceptable sensitivity and can be a potent early detection method for PD.

Indexed as

Extracellular VesiclesParkinson DiseaseAntibodiesEarly DiagnosisFluorescenceHumansLipidsAntibodiesLipidsAlpha-synucleinNanoparticle tracking analysisParkinson’s diseaseProdromalSalivaSmall extracellular vesiclesTRODAT scan

Identifiers

PMID37667227
PMCPMC10478478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.